Meta AnalysisID 6153
骨疏康治疗原发性骨质疏松的疗效与安全性：系统评价与Meta分析
CRD42022356485
What is the efficacy and safety of Gushukang capsule in the treatment of primary osteoporosis?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6153
- Evidence Id
- 14711
- Core Evidence Id
- 14711
- Source Meta Analysis Id
- 6132
- Herb2 Meta Analysis Id
- HBMA006132
- Crd Id
- CRD42022356485
- Title
- Efficacy and Safety of Gushukang in the Treatment ofPrimary Osteoporosis: A Systematic Review and Meta-Analysis
- Review Question
- What is the efficacy and safety of Gushukang capsule in the treatment of primary osteoporosis?
- Study Type Included
- We only included RCTs that investigated the efficacy of Gukang capsule for OP without any limitation regarding the status of publication or language.
- Condition Being Studied
- Osteoporosis (OP), a chronic progressive skeletal disease, gradually manifests as low bone mass and bone microarchitecture deterioration, and consequently increases the susceptibility to fracture due to elevated bone fragility. From the data of National Health and Nutrition Examination Survey (NHANES) 2013–2014, among older adults the prevalence of OP and low bone mass ranged from 6 to 11% and from 28 to 45%, depending on the different locations, such as femur neck, lumbar spine, and either the femur neck or lumbar spine. In Chinese mainland, the incidence of OP fracture also showed steady growth. From 2012 to 2015, the prevalence of OP in China had increased to 27.96%, and the estimated prevalence will exceed 13.6% of Chinese elderly in 2050. According to the results of state-transition models, the substantial economic burden to the global healthcare system of osteoporosis-related fractures will significantly increase over the next decades. Therefore, to strengthen the early management of OP is of great importance. For the efficacy of Gushukang capsules, some experiments have showed that it could promote reproduction of osteoblasts and promote bone formation.
- Participant
- We will include participants diagnosed with primary osteoporosis according to any recognized criterion. Additionally, we will adopt other diagnostic criteria with comparable definitions. Postmenopausal osteoporosis and senile osteoporosis are considered POP.
- Animal
- Human Disease Modelled
- Intervention
- The intervention groups were treated with Gushukang capsules alone or combined with conventional treatments. There are no limitations to the dosage or treatment Gushukang capsules used.
- Comparator Control
- The control groups were treated conventional treatments, placebo or conventional treatments plus placebo.
- Main Outcome
- Primary outcomes are the visual analogue scale and bone mineral density. Measures of effect We will use the mean difference (MD) for continuous outcomes.
- Outcome Measure
- Additional Outcome
- Secondary outcomes are total effective rate and biochemical outcomes. Measures of effect We will use the mean difference (MD) for continuous outcomes. We will use the relative risk (RR) for dichotomous outcomes
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Bone Density Conservation Agents; Drugs, Chinese Herbal; Humans; Osteoporosis; gushukang
- Contact
- Liuding Wang [email protected]
- Organisational Affiliation
- Xiyuan Hospital
- Funding Source
- This research was funded by the project from the China Center for Evidence Based Traditional Chinese Medicine (No. 2020YJSZX-3); 2019 the State Administration of traditional Chinese medicine TCM evidence-based capacity building project (ZZ13-024-3) and the National TCM Leading Personnel Support Program (NATCM Personnel and Education Department [2018] No. 12)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-08-28
- Registration Date
- 2022-09-08
- Anticipated Start Date
- 2022-08-28
- Anticipated Completion Date
- 2022-09-30
- Title Cn
- 骨疏康治疗原发性骨质疏松的疗效与安全性：系统评价与Meta分析
- Title En
- Efficacy and Safety of Gushukang in the Treatment ofPrimary Osteoporosis: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete